Can a 7-Day genomic test improve lymphoma treatment?
NCT ID NCT05464823
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study looks at whether a new genomic test called the Molecular Functional (MF) Portrait can quickly provide useful information for treating lymphoma. Researchers will use tumor tissue already collected from 111 adults with diffuse large B-cell lymphoma to see if test results are available within 7 days. The goal is to learn if this type of testing is practical for guiding care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that rapid genomic testing is feasible for guiding lymphoma treatment decisions.
- What could go wrong
- This is a small feasibility study, not a treatment trial. It only tests if results can be delivered quickly, not whether they improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?